Propanc Biopharma Reports Proenzymes Disrupt Pancreatic Cancer Fibroblasts

Reuters

Dec 22, 2025

<a href="https://laohu8.com/S/PPCB">Propanc Biopharma</a> Reports Proenzymes Disrupt Pancreatic Cancer Fibroblasts

Propanc Biopharma Inc. and its research partners at the Universities of Jaén and Granada have published new findings in the journal Scientific Reports demonstrating the potential impact of pancreatic proenzymes on pancreatic ductal adenocarcinoma (PDAC) fibroblasts. The study shows that Propanc’s PRP, a combination of bovine-derived pancreatic proenzymes trypsinogen and chymotrypsinogen, has multifaceted effects on cancer-associated fibroblasts and tumor cells within the PDAC tumor microenvironment. These results highlight PRP as a promising candidate for disrupting key tumor interactions and suggest its potential as an adjunct therapy for PDAC patients. Propanc plans to begin a Phase 1b clinical study in advanced cancer patients in the third quarter of 2026 to further investigate PRP’s clinical benefits. The research results have already been published and are available online.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Propanc Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9615825) on December 22, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2593548400"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2593548400\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2593548400?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-22 20:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2593548400","market":"nz","top_or_hot":-1,"title":"Propanc Biopharma Reports Proenzymes Disrupt Pancreatic Cancer Fibroblasts","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/PPCB\">Propanc Biopharma</a> Reports Proenzymes Disrupt Pancreatic Cancer Fibroblasts\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/PPCBD\">Propanc Biopharma</a> Inc. and its research partners at the Universities of Jaén and Granada have published new findings in the journal Scientific Reports demonstrating the potential impact of pancreatic proenzymes on pancreatic ductal adenocarcinoma (PDAC) fibroblasts. The study shows that Propanc’s PRP, a combination of bovine-derived pancreatic proenzymes trypsinogen and chymotrypsinogen, has multifaceted effects on cancer-associated fibroblasts and tumor cells within the PDAC tumor microenvironment. These results highlight PRP as a promising candidate for disrupting key tumor interactions and suggest its potential as an adjunct therapy for PDAC patients. Propanc plans to begin a Phase 1b clinical study in advanced cancer patients in the third quarter of 2026 to further investigate PRP’s clinical benefits. The research results have already been published and are available online.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Propanc Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9615825) on December 22, 2025, and is solely responsible for the information contained therein.</span></i>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Propanc Biopharma Reports Proenzymes Disrupt Pancreatic Cancer Fibroblasts</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPropanc Biopharma Reports Proenzymes Disrupt Pancreatic Cancer Fibroblasts\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-22 20:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/PPCB\">Propanc Biopharma</a> Reports Proenzymes Disrupt Pancreatic Cancer Fibroblasts\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/PPCBD\">Propanc Biopharma</a> Inc. and its research partners at the Universities of Jaén and Granada have published new findings in the journal Scientific Reports demonstrating the potential impact of pancreatic proenzymes on pancreatic ductal adenocarcinoma (PDAC) fibroblasts. The study shows that Propanc’s PRP, a combination of bovine-derived pancreatic proenzymes trypsinogen and chymotrypsinogen, has multifaceted effects on cancer-associated fibroblasts and tumor cells within the PDAC tumor microenvironment. These results highlight PRP as a promising candidate for disrupting key tumor interactions and suggest its potential as an adjunct therapy for PDAC patients. Propanc plans to begin a Phase 1b clinical study in advanced cancer patients in the third quarter of 2026 to further investigate PRP’s clinical benefits. The research results have already been published and are available online.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Propanc Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9615825) on December 22, 2025, and is solely responsible for the information contained therein.</span></i>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0314104364.USD","symbol_name":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251222:nNDL9J1sMQ:1","article_id":"2593548400","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2593548400","pubTimestamp":1766404925,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Propanc Biopharma Inc. and its research partners at the Universities of Jaén and Granada have published new findings in the journal Scientific Reports demonstrating the potential impact of pancreatic proenzymes on pancreatic ductal adenocarcinoma  fibroblasts. The study shows that Propanc’s PRP, a combination of bovine-derived pancreatic proenzymes trypsinogen and chymotrypsinogen, has multifaceted effects on cancer-associated fibroblasts and tumor cells within the PDAC tumor microenvironment. These results highlight PRP as a promising candidate for disrupting key tumor interactions and suggest its potential as an adjunct therapy for PDAC patients. Propanc plans to begin a Phase 1b clinical study in advanced cancer patients in the third quarter of 2026 to further investigate PRP’s clinical benefits. The research results have already been published and are available online.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUB","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","BK4588":"碎股","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","BK4112":"金融交易所和数据","PPCB":"Propanc Biopharma, Inc.","BK4585":"ETF&股票定投概念","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","BK4139":"生物科技","NDAQ":"纳斯达克OMX交易所"},"translate_title":"Propanc Biopharma报告前酶破坏胰腺癌成纤维细胞","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"PPCB":0.9},"content_text":"Propanc Biopharma Reports Proenzymes Disrupt Pancreatic Cancer Fibroblasts\n    \n\nPropanc Biopharma Inc. and its research partners at the Universities of Jaén and Granada have published new findings in the journal Scientific Reports demonstrating the potential impact of pancreatic proenzymes on pancreatic ductal adenocarcinoma (PDAC) fibroblasts. The study shows that Propanc’s PRP, a combination of bovine-derived pancreatic proenzymes trypsinogen and chymotrypsinogen, has multifaceted effects on cancer-associated fibroblasts and tumor cells within the PDAC tumor microenvironment. These results highlight PRP as a promising candidate for disrupting key tumor interactions and suggest its potential as an adjunct therapy for PDAC patients. Propanc plans to begin a Phase 1b clinical study in advanced cancer patients in the third quarter of 2026 to further investigate PRP’s clinical benefits. The research results have already been published and are available online.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Propanc Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9615825) on December 22, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}